Stefan Doboczky has served as Chairman of the Board of Directors of Hovione since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman upon assuming the role of Chief Executive Officer.
CordenPharma is investing €80 million at its Caponago, Italy, site, adding a new facility and fill-finish lines to lift sterile injectable capacity to 500 million units/year, backed by shareholder Astorg. The expansion involves two key components to augment manufacturing capacity for sterile injectable drug products.
The investment will reinforce the Bend site as a center of excellence for particle engineering and bioavailability enhancement and create a global manufacturing hub for commercial spray-drying. Lonza will offer a full range of spray-dried dispersion (SDD) capacity to support customers across both clinical and commercial programs.
Under the licensing deal, a subsidiary of GSK will gain global rights to the cancer candidate HMPL-A830, although HUTCHMED will retain development and commercialisation activities in Mainland China, Hong Kong, Macau and Taiwan.
The deal for Merida, which includes upfront and milestone payments, sees Lilly bolster its pipeline with biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions.
